| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ECE1 |
| Uniprot No | P42892 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 90-770aa |
| 氨基酸序列 | QYQTRSPSVC LSEACVSVTS SILSSMDPTV DPCHDFFSYA CGGWIKANPV PDGHSRWGTF SNLWEHNQAI IKHLLENSTA SVSEAERKAQ VYYRACMNET RIEELRAKPL MELIERLGGW NITGPWAKDN FQDTLQVVTA HYRTSPFFSV YVSADSKNSN SNVIQVDQSG LGLPSRDYYL NKTENEKVLT GYLNYMVQLG KLLGGGDEEA IRPQMQQILD FETALANITI PQEKRRDEEL IYHKVTAAEL QTLAPAINWL PFLNTIFYPV EINESEPIVV YDKEYLEQIS TLINTTDRCL LNNYMIWNLV RKTSSFLDQR FQDADEKFME VMYGTKKTCL PRWKFCVSDT ENNLGFALGP MFVKATFAED SKSIATEIIL EIKKAFEESL STLKWMDEET RKSAKEKADA IYNMIGYPNF IMDPKELDKV FNDYTAVPDL YFENAMRFFN FSWRVTADQL RKAPNRDQWS MTPPMVNAYY SPTKNEIVFP AGILQAPFYT RSSPKALNFG GIGVVVGHEL THAFDDQGRE YDKDGNLRPW WKNSSVEAFK RQTECMVEQY SNYSVNGEPV NGRHTLGENI ADNGGLKAAY RAYQNWVKKN GAEHSLPTLG LTNNQLFFLG FAQVWCSVRT PESSHEGLIT DPHSPSRFRV IGSLSNSKEF SEHFRCPPGS PMNPPHKCEV W |
| 预测分子量 | 80 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ECE1重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: "Cloning and functional expression of human endothelin-converting enzyme cDNA"
**作者**: Shimada K, Matsushita Y, Wakabayashi K et al.
**摘要**: 该研究首次报道了人源ECE1的cDNA克隆及哺乳动物细胞重组表达，证实重组酶可将大内皮素-1转化为活性内皮素-1.揭示了其pH依赖性酶活性(J Biol Chem, 1995)。
---
2. **文献名称**: "Recombinant human endothelin-converting enzyme-1: purification and characterization"
**作者**: Schmidt M, Loffler BM, Aebi JD et al.
**摘要**: 研究通过杆状病毒系统表达重组人ECE1.优化纯化流程并分析其酶动力学参数，发现其对大内皮素-1的高效催化活性及金属离子依赖性(Biochem J, 1994)。
---
3. **文献名称**: "Structural determinants of substrate specificity in recombinant endothelin-converting enzyme-1"
**作者**: Emoto N, Yanagisawa M.
**摘要**: 通过定点突变和重组ECE1的功能实验，揭示了酶活性中心的关键结构域(如锌结合位点)对底物识别和催化效率的调控机制(J Biol Chem, 1995)。
---
**备注**：若需扩展，可补充研究ECE1重组蛋白与疾病(如高血压、癌症)关联的文献。建议通过PubMed/Google Scholar检索关键词“recombinant ECE1”获取全文。
Endothelin-converting enzyme 1 (ECE1) is a membrane-bound metalloprotease primarily known for its role in the biosynthesis of endothelin-1 (ET-1), a potent vasoconstrictor peptide involved in cardiovascular regulation. ECE1 catalyzes the proteolytic cleavage of inactive big endothelin-1 (big ET-1) into its biologically active form, ET-1. which binds to endothelin receptors to mediate vascular tone, cell proliferation, and inflammation. Beyond its canonical function, ECE1 has been implicated in diverse physiological and pathological processes, including cancer progression, neuropathic pain, and pulmonary hypertension.
Recombinant ECE1 protein is engineered for research and therapeutic applications, typically expressed in heterologous systems like mammalian or insect cell cultures to ensure proper post-translational modifications. The recombinant form retains enzymatic activity, enabling studies on substrate specificity, inhibitor screening, and structural analysis. Its modular structure includes a short N-terminal cytoplasmic tail, a transmembrane domain, and a large extracellular catalytic domain containing a zinc-binding motif critical for protease activity.
Interest in recombinant ECE1 stems from its dual role as a therapeutic target and a biochemical tool. Inhibitors of ECE1 are explored for treating cardiovascular diseases and cancers driven by ET-1 signaling. Conversely, recombinant ECE1 serves as a reagent to generate ET-1 in vitro for mechanistic studies or drug discovery platforms. Structural studies using recombinant protein have elucidated substrate-binding pockets and conformational dynamics, guiding rational drug design. However, challenges remain in optimizing stability and activity for industrial-scale applications. Ongoing research focuses on engineering variants with enhanced catalytic efficiency or altered specificity, broadening its utility in both basic science and translational medicine.
×
